OncoCyte (OCX) Competitors

OncoCyte (NASDAQ:OCX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.

Is OCX or NVCT more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Nuvectis Pharma's return on equity of -155.80% beat OncoCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OncoCyte	-6,122.29%	-269.32%	-59.71%
Nuvectis Pharma	N/A	-155.80%	-104.02%

Do analysts rate OCX or NVCT?

OncoCyte currently has a consensus price target of $4.56, indicating a potential upside of 42.13%. Nuvectis Pharma has a consensus price target of $15.00, indicating a potential upside of 43.40%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than OncoCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoCyte	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nuvectis Pharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer OCX or NVCT?

In the previous week, OncoCyte had 17 more articles in the media than Nuvectis Pharma. MarketBeat recorded 19 mentions for OncoCyte and 2 mentions for Nuvectis Pharma. OncoCyte's average media sentiment score of 0.31 beat Nuvectis Pharma's score of 0.19 indicating that OncoCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OncoCyte	0 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more risk and volatility, OCX or NVCT?

OncoCyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in OCX or NVCT?

55.3% of OncoCyte shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer OCX or NVCT?

OncoCyte and Nuvectis Pharma both received 11 outperform votes by MarketBeat users. However, 91.67% of users gave Nuvectis Pharma an outperform vote while only 9.91% of users gave OncoCyte an outperform vote.

Company	Underperform	Outperform
OncoCyte	Outperform Votes 11 9.91%	Underperform Votes 100 90.09%
Nuvectis Pharma	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%

Which has better earnings & valuation, OCX or NVCT?

Nuvectis Pharma has lower revenue, but higher earnings than OncoCyte. Nuvectis Pharma is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoCyte	$1.88M	29.78	-$27.78M	-$4.40	-0.73
Nuvectis Pharma	N/A	N/A	-$22.26M	-$1.11	-9.42

Summary

Nuvectis Pharma beats OncoCyte on 9 of the 16 factors compared between the two stocks.